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Abstract 
Tumour microenvironment is known to be acidic due to high glycolytic 
rates of tumour cells. Monocarboxylate transporters (MCTs) play a role in 
extracellular acidification, which is widely known to be involved in tumour 
progression. Recently, we have described the up-regulation of MCT1 in breast 
carcinomas and its association with poor prognostic variables. Thus, we aimed 
to evaluate the effect of lactate transport inhibition in human breast cancer cell 
lines. The effect of alpha-cyano-4-hydroxycinnamate (CHC), Quercetin and 
Lonidamine, on cell viability, metabolism, proliferation, apoptosis, migration and 
invasion was assessed in a panel of different breast cancer cell lines. 
MCT1, MCT4 and CD147 were differently expressed among the breast 
cancer cell lines and, as expected, different sensitivities were observed for the 
three inhibitors. Interestingly, in the most sensitive cell lines, lactate transport 
inhibition induced a decrease in cell proliferation, migration and invasion, as 
well as an increase in cell death. 
The results here obtained support targeting lactate transport as a 
strategy to treat breast cancer, with special emphasis on basal-like subtype, 
which so far does not have a specific molecular therapy. 
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Introduction 
Increased glucose uptake is a widely described phenomenon in cancer 
cells, being the rationale behind the whole-body non-invasive positron emission 
imaging technique, using 18F-fluorodeoxyglucose (FDG-PET). This technique is 
useful in the diagnosis and prognosis of breast cancer, especially regarding the 
detection of distant metastases, recurrent disease as well as monitoring therapy 
response (Jadvar et al., 2009). This increased uptake of glucose, especially 
through glucose transporter 1 (GLUT1), is a consequence of an increased 
glycolytic metabolism that generates acids inside the cell. This fact leads to up-
regulation of some pH regulators, like carbonic anhydrase IX (CAIX) 
(Pouyssegur et al., 2006), to maintain the intracellular physiological pH, causing 
extracellular acidosis. The increased glycolytic metabolism ultimately leads to 
an increase in lactate release by cancer cells, also contributing to 
microenvironmental acidosis, as well as increased invasion (Stern et al., 2002) 
and suppression of anticancer immune response (Fischer et al., 2007). In this 
context, lactate has a central role in cancer aggressiveness and lactate 
transporters (monocarboxylate transporters, MCTs) are currently seen as 
potential therapeutic targets in cancer treatment, with promising results using in 
vitro and in vivo models (Mathupala et al., 2004; Colen et al., 2011; Colen et al., 
2006; Fang et al., 2006; Mathupala et al., 2007; Sonveaux et al., 2008). There 
is a clinical trial ongoing using a specific MCT1/MCT2 inhibitor (Jones & 
Schulze, 2012). 
MCTs belong to a family of 14 members, with isoforms 1 to 4 being 
lactate proton symporters that exhibit different affinities for lactate (Halestrap & 
Meredith, 2004).  As the isoforms responsible for lactate afflux, MCT1 and 
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MCT4 are probably the most promising in the cancer context and reports on 
MCT1 and MCT4 upregulation in a variety of tumours are becoming more 
frequent (Mathupala et al., 2004; Fang et al., 2006; Koukourakis et al., 2007; 
Koukourakis et al., 2006; Pinheiro et al., 2008b; Pinheiro et al., 2008a; Pinheiro 
et al., 2010; Pinheiro et al., 2012). Importantly, we have described association 
of MCTs, especially MCT1, with poor prognostic variables (Pinheiro et al., 2009; 
Pinheiro et al., 2008b; Pinheiro et al., 2010; de Oliveira et al., 2012), reinforcing 
the potential of MCT1 as a cancer therapeutic target. Recently, our group 
described an increase of MCT1 expression in breast carcinomas, when 
comparing with normal tissue. This enhanced MCT1 expression, as well as the 
expression of CD147 (MCT1/MCT4 chaperone (Kirk et al., 2000; Gallagher et 
al., 2007)), were associated with basal-like subtype tumours and other poor 
prognostic parameters (Pinheiro et al., 2010). Additionally, we found that MCT1, 
but not MCT4, was associated with GLUT1 and CAIX expressions, pointing to a 
role of MCT1 in the hyperglycolytic and acid-resistant phenotype characteristic 
of less oxygenated (Pinheiro et al., 2011), instead of oxygenated cancer cells as 
pointed by others (Sonveaux et al., 2008).  
Over the last years, different approaches have been used to inhibit 
lactate efflux from cancer cells, including MCT small-molecule inhibitors like α-
cyano-4-hydroxycinnamic acid (CHC) (Colen et al., 2006; Sonveaux et al., 
2008), Lonidamine (Fang et al., 2006; Ben-Horin et al., 1995; Ben-Yoseph et 
al., 1998), flavonoids like Quercetin (Belt et al., 1979; Deuticke, 1982; Wang & 
Morris, 2007), and MCT small-interfering RNA (siRNA) (Fang et al., 2006; 
Mathupala et al., 2004; Sonveaux et al., 2008). Inhibition of MCTs will have a 
direct effect on lactate transport, as well as on pH homeostasis, therefore 
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having an important effect on cancer cell viability. In fact, MCT inhibition studies 
are providing evidence for this strategy in the reduction of tumour malignancy, 
enhancement of radio-sensitivity and induction of cell-death (Mathupala et al., 
2007).  
Despite the promising results with MCT inhibition in cancer, more efforts 
are needed to support inhibition of lactate transport and pH regulation as an 
alternative therapeutic strategy in cancer treatment. In the present work we 
were able to demonstrate the potential of MCT inhibitors in reducing breast 
cancer cell proliferation, migration and invasion as well as inducing cell death. 
 
Materials and Methods 
Cell lines and culture conditions 
The human breast cancer cell lines MDA-MB-468, MDA-MB-231, 
Hs578T, BT-20, MCF-7/AZ and SkBr3 were obtained from ATCC or from 
collections developed at Drs Elena Moisseva (Cancer Biomarkers and 
Prevention Group, Departments of Biochemistry and Cancer Studies, University 
of Leicester, UK), Marc Mareel (Laboratory of Experimental Cancerology, Ghent 
University Hospital, Belgium) and Eric Lam (Imperial College School of 
Medicine, Hammersmith Hospital, London, UK). The characteristics of each cell 
line are presented in Table 1. 
All cell lines were routinely cultured in DMEM (Invitrogen), supplemented 
with 10% Fetal Bovine Serum (FBS, Invitrogen) and 1% antibiotic solution 
(penicillin–streptomycin, Invitrogen), in a 37ºC humidified atmosphere with 5% 
CO2.  
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Drugs 
Stock solutions of CHC, Quercetin and Lonidamine (Sigma-Aldrich) were 
prepared in dimethylsulfoxide (DMSO, Sigma-Aldrich) and stored at -20ºC until 
use. Working solutions were freshly prepared in culture medium without serum. 
DMSO concentration in the cell culture medium never exceeded 1%. All 
controls were performed using DMSO alone (vehicle). 
 
Downregulation of MCT1 expression 
Silencing of MCT1 expression was achieved using siRNA (siRNA for 
MCT1, #4390824, Ambion; scramble siRNA, #4390843, Ambion), using 
lipofectamine (RNAiMAX 13778-075, Invitrogen) as permeabilization agent, 
according to the manufacturer’s instructions. 
 
 
Evaluation of the metabolic behaviour of human breast cancer cell 
lines 
Glucose and lactate quantification 
The metabolic behaviour of the different cell lines was determined by 
assessing extracellular amounts of glucose and lactate. Glucose and lactate 
were quantified using commercial kits (Roche and SpinReact, respectively), 
according to the manufacturer’s instructions, as previously described (Miranda-
Goncalves et al., 2013). Results are expressed as total µg of three independent 
experiments. 
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Protein expression assessment 
Paraffin cytoblock and immunocytochemistry 
Concentrated cell suspensions were used to prepare paraffin cytoblocks 
for immunocytochemistry for MCT1, MCT4 and CD147, as previously described 
(Miranda-Goncalves et al., 2013). See Table 12 for immunocytochemistry 
details. Negative controls were performed by using adequate serum controls for 
the primary antibodies (N1698 and N1699, Dako). Cytoblock sections were 
counterstained with haematoxylin and permanently mounted. Cells were 
evaluated for positive expression, distinguishing cytoplasmic from membrane 
expression. 
Western-blot  
Western-blot was performed as previously described (Miranda-
Goncalves et al., 2013), using the same antibodies as for immunocytochemistry 
(anti-MCT1, 1:200; anti-MCT4, 1:500; anti-CD147, 1:500). Goat anti-actin 
(1:500, sc-1616, Santa Cruz Biotechnology) was used as loading control.  
Assessment of the effect of lactate transport inhibitors 
IC50 determination 
Cells were plated in 96-well plates and allowed to adhere overnight in 
complete DMEM medium, prior to incubation with culture medium containing 3-
15 mM of CHC, 10-100 µM of Quercetin and 50-300 µM of Lonidamine. The 
effect of CHC on total biomass, measured by the Sulforhodamine B assay 
(TOX-6, Sigma-Aldrich), was evaluated after 24 hours of treatment, while for 
Quercetin and Lonidamine the time of treatment was 48 hours. IC50 values were 
estimated with the GraphPad Prism 5 software, applying a sigmoidal dose-
response (variable slope) nonlinear regression, after logarithmic transformation. 
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Metabolic profiling 
After reaching confluence, cells were incubated with the IC50 value for 
each inhibitor and each cell line and aliquots of cell culture media were retrieved 
after 4, 8, 12 and 24 hours, assuring confluences similar to the ones observed 
in the control. Glucose and lactate were quantified as mentioned above.  
Cell proliferation assay 
Proliferation of cells sensitive to inhibitors’ treatment was assessed by 
bromodeoxyuridine (BrdU) incorporation, after treatment with CHC, Quercetin 
and Lonidamine at IC50 concentrations (24 hours for CHC and 48 hours for 
Quercetin and Lonidamine), as previously described (Miranda-Goncalves et al., 
2013). 
Cell death assay  
Cells were treated with CHC for 24 hours, and Quercetin and Lonidamine 
for 48 hours (IC50 concentrations) and cell death was assessed by simultaneous 
staining with FITC annexin-V and propidium iodide, as previously described 
(Miranda-Goncalves et al., 2013).  
Wound-healing assay 
Cell migration was assessed by the wound-healing assay, as previously 
described (Miranda-Goncalves et al., 2013). Cells were exposed to half of the 
IC50 for CHC (to avoid excessive proliferation inhibition and cell death) and the 
IC50 concentrations for Quercetin and Lonidamine. The ‘‘wounded’’ areas were 
photographed at 0, 12 and 24 hours. 
Invasion assay 
Cell invasion assay was performed with the sensitive cell lines with 
invading capacity (MDA-MB-468, MDA-MB-231 and Hs578T), using 24 well BD 
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Biocoat Matrigel Invasion Chambers (BD Biosciences), according to the 
manufacturer’s instructions, as previously described (Miranda-Goncalves et al., 
2013). Cells were seeded in medium containing half of the IC50 concentration 
for CHC, and the IC50 concentrations for Quercetin and Lonidamine, during 24 
hours. 
Statistical analysis 
Data from three independent experiments, each one in triplicate, was 
stored in GraphPad Prism 5 software. All conditions were examined for 
statistical significance using two-tailed Student’s t-test for mean comparison, 
being the threshold for significance p values <0.05. 
 
Results 
Cells with higher rates of glucose consumption produced more lactate 
Metabolic phenotype of breast cancer cell lines 
As depicted in Figure 1A, membrane expression of MCT1 was only 
observed in MDA-MB-468, Hs578T, BT20 and, at a very low level, in MCF-7/AZ 
cell lines, while MCT4 was only clearly expressed at the plasma membrane of 
MDA-MB-231 and SkBr3 cells. CD147 was observed in the plasma membrane 
of all cell lines. MCT2 expression was not found in any of the cell lines analysed 
in the present study (data not shown). Some intracellular expression was also 
observed for these markers in some cell lines. Western-blot analysis confirmed 
the different levels of expression observed by immunocytochemistry (Figure 
1B).  
The cell lines studied exhibited different levels of glycolytic metabolism 
(Figure 1C). As expected, cells with higher rates of glucose consumption also 
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produced more lactate; MDA-MB-468 and SkBr3 showed the highest glucose 
consumption rates, followed by Hs578T and MCF-7/AZ, while MDA-MB-231 
and BT20 presented the lowest consumption rates. In accordance, MDA-MB-
468, SkBr3 and Hs578T produced more lactate than MCF-7/AZ, BT20 and 
MDA-MB-231 by this order. 
 
Inhibition of lactate transport decreased glucose consumption and 
lactate production, in the most glycolytic cells 
Effect of lactate transport inhibition on cell metabolism 
Breast cancer cell lines were treated once with the lactate transport 
inhibitors CHC, Quercetin and Lonidamine at increasing concentrations and IC50 
values were estimated by evaluating total cell biomass (Table 32 ). The IC50 
values show that MDA-MB-468, MDA-MB-231 and Hs578T cells were sensitive 
to CHC, Quercetin, and Lonidamine. MCF-7/AZ cells showed IC50 values only 
for CHC and Lonidamine, while sensitivity to Quercetin was not enough to 
estimate the IC50 within the range of concentrations used, and the same was 
observed for BT20 with all the inhibitors used. SkBr3 showed high IC50 values 
for both Quercetin and Lonidamine.  
To understand if the induced-inhibitory effect in the different cell lines 
was due to metabolic disturbance, glucose consumption and lactate production 
were analysed (Figure 2). Only MDA-MB-468 and Hs578T cells showed a 
significant decrease in both glucose consumption and lactate production, after 
treatment with the 3 inhibitors (Figure 2A and 2B, respectively). MCF-7/AZ also 
showed a significant decrease in glucose consumption and lactate production 
after CHC and Lonidamine treatment, but not after Quercetin treatment, which 
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is in accordance with the effect of Quercetin on MCF-7/AZ biomass. In 
accordance to the higher IC50 values determined for Quercetin and Lonidamine 
in SkBr3 cell line, the glycolytic metabolism was only disturbed in this cell line 
after treatment with CHC. BT20 cells, with a very low sensitivity to the inhibitors, 
also showed a decrease in lactate production after CHC and Quercetin 
treatment, but with no decrease in glucose consumption. Surprisingly, MDA-
MB-231 cell line, with high sensitivity to CHC and Quercetin, showed no 
alterations at the metabolic level after treatment with either inhibitor. Metabolism 
assay confirmed that half of the CHC IC50 was also able do significantly inhibit 
lactate efflux (Supplementary Figure 1A). 
 
Lactate transport inhibition reduced cancer cell aggressiveness 
Effect of lactate transport inhibition on cancer cell biological behaviour 
After assessing the sensitivity to the different inhibitors and the metabolic 
impact of this inhibition, the effect of the inhibitors was further evaluated for 
different tumour cell aggressiveness parameters in the most sensitive cells lines 
and whose metabolism was perturbed. 
Figure 3A shows that all inhibitors induced a significant decrease in cell 
proliferation, which was more evident for Lonidamine in MDA-MB-468 and 
Hs578T cells. CHC induced a prominent decrease in the proliferation of MCF-
7/AZ and SkBr3 cells. 
All inhibitors induced a significant increase in cell death in Hs578T cells, 
while only Quercetin induced a significant increase in cell death in MDA-MB-
468. Interestingly, MCF-7/AZ and SkBr3 cell death was not affected by the 
treatment with the inhibitors (Figure 3B). 
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The influence of lactate transport inhibition on cell migration and invasion 
was also assessed. Importantly, the 3 inhibitors induced a significant decrease 
in cell migration (Figure 4 and Supplementary Figure 2). Additionally, both 
Quercetin and Lonidamine induced a significant decrease in cell invasion for the 
2 invading cell lines analysed (higher effect for Lonidamine), while results on 
CHC were not consistent, as CHC induced a decrease in MDA-MB-468 
invasion and had no effect on Hs578T (Figure 5 and Supplementary Figure 3). 
 
Downregulation of MCT1 decreased lactate production and cell 
aggressiveness  
In order to validate that the previous results were a consequence of 
MCT1 activity inhibition, downregulation of MCT1 expression with siRNA was 
performed in Hs578T cells, which express MCT1 at the plasma membrane. A 
effective reduction in MCT1 expression was observed upon siMCT1 targeting 
(84.2%), as well as in CD147 expression (65.5%) (Figure 6A). MCT4 
expression levels were not altered with MCT1 downregulation. Similarly to 
MCT1 activity inhibition, MCT1 downregulation significantly decreased lactate 
production, after 24hours of silencing however, glucose levels were not affected 
(Figure 6B). Importantly, there was a decrease in cell proliferation and migration 
capacity (Figure 6C and 6D), similarly to the results obtained with inhibition of 
MCT1 activity. 
 
Discussion 
Basal-like tumours have an aggressive clinical behaviour (Sotiriou et al., 
2003; Sorlie et al., 2001; Sorlie et al., 2003) and, in contrast to other molecular 
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subtypes, do not have a specific molecular therapy (Matos et al., 2005; Paredes 
et al., 2007). This entails the search for new molecular targets in this aggressive 
group of tumours, and, considering the increased expression of MCT1 in basal-
like tumours (Pinheiro et al., 2010), as well as recent evidence showing MCTs 
as effective anti-cancer targets (Mathupala et al., 2004; Colen et al., 2006; Fang 
et al., 2006; Sonveaux et al., 2008), MCT1 emerges as a promising therapeutic 
target that needs to be further explored in breast cancer. 
In the present work, we analysed MCT1 and MCT4 expression, as well 
as the expression of other relevant proteins in cancer metabolism, in a variety of 
human breast cancer cell lines. Strong plasma membrane expression of MCT1 
was found in MDA-MB-468, Hs578T and BT20 (basal-like subtype cells), in 
accordance with our findings in human breast carcinoma samples (Pinheiro et 
al., 2010). In MDA-MB-231, also basal-like subtype cells, MCT1 was not 
detected, as described by others (Asada et al., 2003; Gallagher et al., 2007; 
Hussien & Brooks, 2011), and the same was observed for the Her2 positive 
subtype cell line (SkBr3). In contrast, MCT4 was strongly expressed at the 
plasma membrane in MDA-MB-231, as described by others (Hussien & Brooks, 
2011), as well as in SkBr3. Therefore, it seems that the plasma expression of 
these two isoforms is mutually exclusive in breast cancer, suggesting different 
mechanisms of regulation. Importantly, we should not ignore the presence of 
intracellular expression of MCTs, especially MCT4. Actually, a recent study 
shows mitochondrial expression of MCT2 and MCT4 in two breast cancer cell 
lines (MCF-7 and MDA-MB-231, pointing to a role of MCTs in the mitochondria 
(Hussien & Brooks, 2011). Additionally, two other studies have described a 
mitochondrial pyruvate carrier, which is a different protein than MCTs (Herzig et 
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al., 2012; Bricker et al., 2012). However, additional studies are required to 
elucidate if MCTs are working together, in parallel or performing the transport of 
different substrates. Nevertheless, considering that CHC is incapable of 
crossing the plasma membrane, acting only outside the cell (Colen et al., 2006; 
Colen et al., 2011). Thus, when using this inhibitor, we believe that we are 
evaluating only the inhibition of MCT1 activity at the plasma membrane. 
To compare with CHC-induced effects and validate our results 
concerning lactate transport inhibition in breast cancer cells, we used additional 
drugs described as lactate transport inhibitors, Quercetin and Lonidamine. Our 
results show that the human breast cancer cells studied have different 
responses to the inhibitors and the underlying mechanisms seem to vary among 
them. In fact, the most sensitive cell line to both CHC and Quercetin, MDA-MB-
231, besides being negative for MCT1 and producing less lactate than the other 
lines, showed no alterations in glucose consumption or lactate production after 
treatment, indicating that other mechanisms, besides lactate transport inhibition, 
may account for CHC and Quercetin effects on this cell line. In contrast, MDA-
MB-468 and Hs578T, both basal-like subtype cell lines with MCT1 positive 
plasma membrane expression and a more pronounced glycolytic phenotype, 
suffered a significant decrease in glucose consumption and lactate production, 
accompanied by a decrease in total biomass, after exposure to the lactate 
transporter inhibitors. This was the expected result in a highly glycolytic cell line 
after MCT1 inhibition. The blockade of lactate efflux likely led to accumulation of 
lactate in the cytoplasm, arresting glycolysis, with subsequent decrease in 
glucose uptake. Unexpectedly, SkBr3 was sensitive to inhibitor-induced 
decrease in total biomass in a metabolic dependent manner (although at a 
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lower magnitude than MDA-MB-468 or Hs578T and not for the 3 inhibitors), 
albeit having undetectable MCT1 expression at the plasma membrane. MCT4 
could be another CHC target; however, Ki values for MCT4 are 5-10 times 
higher than for MCT1 (Halestrap, 2012), ranging from 50 to 100 mM, 
concentrations not reached in the present assays. Additional targets, also 
affecting cancer cell metabolism, should be behind these effects. Intriguingly, 
BT20 basal-like subtype cells, although highly positive for MCT1, were 
insensitive to treatment with all inhibitors. The reason for this insensitivity 
remains unclear. This may be due to the low proliferative rate of this cell line, 
accompanied by the low glycolytic metabolism. These cells could also rely on 
an alternative source of energy present in the culture medium that is also a 
substrate for MCT1, such as pyruvate. To note that we are evaluating 
extracellular lactate accumulation and these lactate concentrations could be a 
result of both lactate production and removal. However, in the presence of 
glucose, these cells will prefer to consume glucose over lactate, being some cell 
lines even not able to consume lactate. 
Although the effect on cell metabolism is extremely important to 
understand the mechanisms of action of the different inhibitors, it was also 
crucial to unveil the contribution of MCT inhibition to other aggressiveness 
parameters, such as cell proliferation, death, migration and invasion. 
Importantly, we observed that the 3 inhibitors were able to inhibit proliferation, 
migration and invasion, as well as induce cell death in breast cancer cells, being 
this effect more pronounced in MDA-MB-468 cells. As inhibition of MCTs will 
affect both lactate and proton efflux, intracellular accumulation of lactate will 
lead to glycolysis arrest and consequent decrease in cell proliferation, as well 
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as cell death induced by intracellular acidification. Also, the decreased migration 
and invasion capacity after lactate transport inhibition are in accordance with 
the contribution of both lactate and acidic microenvironment to the increased 
migrating and invasive phenotypes of cancer cells (Rofstad et al., 2006; 
Walenta et al., 2002).  
In general, we could observe that CHC has a broader effect on the 
behaviour of the breast cancer cells used in this study. Although used to target 
the same key metabolic proteins (MCTs), CHC, Quercetin and Lonidamine 
seem to act by different mechanisms, as the same cell line responds differently 
to each inhibitor. In fact, other metabolic targets have been described for these 
inhibitors that could mediate the breast cancer cell altered phenotype 
associated with metabolic disturbance. Although being the most commonly 
used MCT1 inhibitor, CHC has also been described as a potent inhibitor of the 
mitochondrial pyruvate transporter (Halestrap & Denton, 1974); however, 
permeability studies carried out by others show that CHC is not internalised by 
U-87MG glioma cells (Colen et al., 2006). Additionally, CHC has also been point 
out as an inhibitor of the anion exchanger 1 (AE1) (Deuticke, 1982), an 
important pH regulator that is responsible for Cl-/HCO3
- membrane exchange 
(Kopito, 1990). Different effects have been identified as mediating the 
antitumour activity of Quercetin, including cell cycle arrest (Yang et al., 2006) 
and apoptosis (Yang et al., 2006; Granado-Serrano et al., 2006), as well as 
inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (Granado-
Serrano et al., 2006). However, we observed that Quercetin only affected the 
MCT1 positive breast cancer cells at the metabolic level, with no disturbance in 
the metabolic behaviour of MCT1 negative breast cancer cell lines, indicating 
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some preference for MCT inhibition. Regarding Lonidamine, although results 
indicate that inhibition of lactate transport and its accumulation are the major 
metabolic changes induced by Lonidamine (Ben-Horin et al., 1995), an 
additional glycolytic protein, hexokinase II, can be also targeted (Floridi et al., 
1981). 
Therefore, further studies to unveil additional targets of the inhibitors 
used in this study are warranted. Also, more specific approaches to target 
MCTs such as interference RNA, should be used to further elucidate the role of 
MCTs in breast cancer cell survival and aggressiveness. 
To better understand the effect of the MCT inhibitors used in this work, 
downregulation of MCT1 was performed in Hs578T cells, which presents MCT1 
expression at plasma membrane. Similarly to activity inhibition results, MCT1 
downregulation decreased proliferation and migration likely due to the decrease 
in lactate production. Other studies corroborate these results, providing 
evidence for the specificity of CHC to inhibit MCT1and the importance of MCT1 
downregulation (Colen et al., 2011; Mathupala et al., 2004; Miranda-Goncalves 
et al., 2013). 
In the present study, by targeting lactate efflux, we took a step forward to 
support targeting metabolism as an effective way to control cancer and, in 
particular, to consider the development of therapeutic approaches targeting 
MCT1 to treat basal-like breast tumours.  
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Figure Legends 
 
Figure 1. Characterisation of the metabolic profile of the breast cancer cell 
lines. Immunocytochemical expression of MCT1, MCT4 and CD147 in human 
breast carcinoma cell lines (scale bar 20µm) MCT1 expression was mainly 
found at the plasma membrane of MDA-MB-468, BT20 and Hs578T cells, while 
MCT4 plasma membrane staining was found in MDA-MB-231 and SkBr3. 
CD147 was mainly observed at the plasma membrane of tumour cells, at 
varying levels, with exception of MCF-7/AZ which is negative for 
immunocytochemical expression of this protein (A). MCT1 (50 kDa), MCT4 (52 
kDa) and CD147 (50-60 kDa for the highly glycosylated and 42 kDa for the low 
glycosylated form) protein expression was detected by Western blot in cell 
lysates (B). Extracellular amounts of glucose and lactate in the different human 
breast cancer cell lines, along time (4, 8, 12 and 24h). Values are expressed as 
mean ± SEM (C). 
 
Figure 2. Effect of MCT inhibitors on glycolytic metabolism. Extracellular 
amounts of consumed glucose (A) and lactate produced (B) in the different 
human breast cancer cell lines. Cell lines were incubated with respective IC50 
for CHC, Quercetin and Lonidamine during 24 hours, and glucose and lactate 
were quantified along time (4, 8, 12 and 24 hours). Values are expressed as 
mean ± SEM. p<0.05; *Control (DMSO) vs CHC; # Control (DMSO) vs 
Quercetin; $ Control (DMSO) vs Lonidamine. 
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Figure 3.  Effect of MCT inhibitors on cell proliferation and cell death. Cell 
lines were treated during 24 hours with CHC (IC50/2) and during 48 hours with 
Quercetin/Lonidamine (IC50). Cell proliferation (A) was evaluated by BrdU 
incorporation and cell death (B) by Annexin V/PI. Values are expressed as 
mean ± SEM. *p<0.05 compared to control (DMSO). 
 
Figure 4. Effect of MCT inhibitors on cell migration. Cell migration was 
evaluated by the wound-healing assay in treated cells during 24 hours with the 
IC50/2 for CHC and the IC50 for Quercetin and Lonidamine. *p<0.05 compared to 
control (DMSO) (A). Pictures represent Hs578T cell migration captured at 0, 12 
and 24 hours (scale bar 100µm) (B). Pictures of the remaining cell lines are 
available in Supplemental Figure 2.  
 
Figure 5. Effect of MCT inhibitors on cell invasion capacity. Cells were 
treated with the respective IC50/2 (CHC) and IC50 (Quercetin/Lonidamine) 
values, for 24 hours, in matrigel invasion chambers. *p<0.05 compared to 
control (DMSO) (A). Pictures represent Hs578T cell invasion at 24 hours (scale 
bar 100µm and 2000 µm) (B). Pictures representing MDA-MB-468 are available 
in Supplemental Figure 3. 
 
Figure 6. Downregulation of MCT1 in Hs578T. Cells were transfected with 
scramble or siMCT1, and expression of MCT1, MCT4 and CD147 was 
evaluated after 24 hours (A).Effect of MCT1 downregulation in cell metabolism 
(B), proliferation (C) and migration (D).*p<0.05 siMCT1 cells compared to 
scramble. 
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Table 1- Details of the origin, clinical, and pathological features of the tumours 
used to establish the breast cancer cell lines used in present study (Neve et al., 
2006). 
Cell line Origin 
Age 
(years) 
Pathology Cancer subtype ER status 
MDA-MB-468 
Metastatic site 
(pleural effusion) 
51 Adenocarcinoma Basal A - 
MDA-MB-231    
Metastatic site 
(pleural effusion) 
51 Adenocarcinoma Basal B  - 
Hs578T           Breast 74 
Invasive ductal 
carcinoma 
Basal B  - 
BT20             Breast 74 
Invasive ductal 
carcinoma 
Basal A - 
MCF-7/AZ  
Metastatic site 
(pleural effusion) 
69 
Invasive ductal 
carcinoma 
Luminal + 
SkBr3            
Metastatic site 
(pleural effusion) 
43 Adenocarcinoma Luminal (Her2+) - 
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Table 21- Details of the immunocytochemical procedure for MCT1, MCT4 and CD147. 
 
 
 
 
 
 
Protein 
Positive 
Control 
Antigen 
retrieval 
Peroxidase 
inactivation 
Detection system 
Primary Antibody 
Company 
(reference) 
Dilution 
and 
incubation 
time 
MCT1 Colon 
carcinoma 
Citrate buffer 
(10mM, pH=6) 
98°C; 20 min 
0.3% H2O2 in 
methanol,  
30 min 
R.T.U. VECTASTAIN 
Elite ABC Kit 
(VECTOR 
laboratories) 
Santa Cruz 
Biotechnology 
(sc-365501) 
1:500, 
overnight, 
RT 
 
MCT4 Colon 
carcinoma 
Citrate buffer 
(10mM, pH=6) 
98°C; 20 min 
3% H2O2 in 
methanol,  
10 min 
Ultravision 
Detection System 
Anti-polyvalent, 
HRP 
(Lab Vision 
Corporation) 
Santa Cruz 
Biotechnology 
(sc-50329) 
1:500, 
2 hours, 
RT 
CD147 Colon 
carcinoma 
EDTA  
(1mM, pH=8) 
98°C; 15 min 
3% H2O2 in 
methanol,  
10 min 
R.T.U. VECTASTAIN 
Elite ABC Kit 
(VECTOR 
laboratories) 
Santa Cruz 
Biotechnology 
(sc-71038) 
1:400, 
overnight, 
RT 
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Table 32- IC50 values for CHC, Quercetin and Lonidamine for each cell line. 
 
Cell lines  
CHC  Quercetin  Lonidamine  
IC50 value 
calculated  
IC50 value 
used  
IC50 value 
calculated  
IC50 value 
used  
IC50 value 
calculated  
IC50 value 
used  
MDA-MB-468  9.6mM  10 mM  49.64 µM  50 µM  95.84 µM  100 µM  
MDA-MB-231  5.33mM  5 mM  40.65 µM  40 µM  126.1 µM  125 µM  
Hs578T  11.45mM  10 mM  39.88 µM  40 µM  124.5 µM  125 µM  
BT20  >15mM  10 mM*  >100 µM  50 µM*  >300 µM  125 µM*  
MCF-7/AZ  9.44mM  10 mM  >100 µM  50 µM*  123.6 µM  125 µM  
SkBr3  12.39mM  10 mM  94.05 µM  50 µM*  237.8 µM  125 µM*  
*- These values do not correspond to the IC50 value. For these cell lines, the highest IC50 value obtained 
for the other cell lines was used.  
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Figure 1. Characterisation of the metabolic profile of the breast cancer cell lines. Immunocytochemical 
expression of MCT1, MCT4 and CD147 in human breast carcinoma cell lines (scale bar 20µm) (A). MCT1 (50 
kDa), MCT4 (52 kDa) and CD147 (50-60 kDa for the highly glycosylated and 42 kDa for the low glycosylated 
form) protein expression was detected by Western blot in cell lysates (B). Extracellular amounts of glucose 
and lactate in the different human breast cancer cell lines, along time (4, 8, 12 and 24h). Values are 
expressed as mean ± SEM (C).  
173x137mm (300 x 300 DPI)  
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Figure 2. Effect of MCT inhibitors on glycolytic metabolism. Extracellular amounts of consumed glucose (A) 
and lactate produced (B) in the different human breast cancer cell lines. Cell lines were incubated with 
respective IC50 for CHC, Quercetin and Lonidamine during 24 hours, and glucose and lactate were 
quantified along time (4, 8, 12 and 24 hours). Values are expressed as mean ± SEM. p<0.05; *Control 
(DMSO) vs CHC; # Control (DMSO) vs Quercetin; $ Control (DMSO) vs Lonidamine.  
245x327mm (300 x 300 DPI)  
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Figure 3. Effect of MCT inhibitors on cell proliferation and cell death. Cell lines were treated during 24 hours 
with CHC (IC50/2) and during 48 hours with Quercetin/Lonidamine (IC50). Cell proliferation (A) was 
evaluated by BrdU incorporation and cell death (B) by Annexin V/PI. Values are expressed as mean ± SEM. 
*p<0.05 compared to control (DMSO).  
111x58mm (300 x 300 DPI)  
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Figure 4. Effect of MCT inhibitors on cell migration. Cell migration was evaluated by the wound-healing assay 
in treated cells during 24 hours with the IC50/2 for CHC and the IC50 for Quercetin and Lonidamine. 
*p<0.05 compared to control (DMSO) (A). Pictures represent Hs578T cell migration captured at 0, 12 and 
24 hours (scale bar 100µm) (B). Pictures of the remaining cell lines are available in Supplemental Figure 2.  
124x62mm (300 x 300 DPI)  
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Figure 5. Effect of MCT inhibitors on cell invasion capacity. Cells were treated with the respective IC50/2 
(CHC) and IC50 (Quercetin/Lonidamine) values, for 24 hours, in matrigel invasion chambers. *p<0.05 
compared to control (DMSO) (A). Pictures represent Hs578T cell invasion at 24 hours (scale bar 100µm and 
2000 µm) (B). Pictures representing MDA-MB-468 are available in Supplemental Figure 3.  
173x80mm (300 x 300 DPI)  
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Figure 6. Downregulation of MCT1 in Hs578T. Cells were transfected with scramble or siMCT1, and 
expression of MCT1, MCT4 and CD147 was evaluated after 24 hours (A).Effect of MCT1 downregulation in 
cell metabolism (B), proliferation (C) and migration (D).*p<0.05 siMCT1 cells compared to scramble.  
153x155mm (300 x 300 DPI)  
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Supplemental Figure 1. Effect of CHC inhibitor on glycolitic metabolism. Extracellular amounts of consumed 
glucose (A) and lactate produced (B) in the different human breast cancer cell lines. Cell lines were 
incubated with respective IC50/2 for CHC, during 24 hours, and glucose and lactate were quantified along 
time (4, 8, 12 and 24 hours). Values are expressed as mean ± SEM. p<0.05; *Control (DMSO) vs CHC.  
219x271mm (300 x 300 DPI)  
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Supplemental Figure 2. Effect of MCT inhibitors on cell migration. Cell migration was evaluated by the 
wound-healing assay in treated cells during 24 hours with the IC50/2 for CHC and the IC50 for Quercetin 
and Lonidamine. Pictures represent MDA-MB-468, MCF-7/AZ and SkBr3 cell migration captured at 0, 12 and 
24 hours (scale bar 100µm).Supplemental Figure 2. Effect of MCT inhibitors on cell migration. Cell migration 
was evaluated by the wound-healing assay in treated cells during 24 hours with the IC50/2 for CHC and the 
IC50 for Quercetin and Lonidamine. Pictures represent MDA-MB-468, MCF-7/AZ and SkBr3 cell migration 
captured at 0, 12 and 24 hours (scale bar 100µm).  
151x145mm (300 x 300 DPI)  
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Supplemental Figure 3. Effect of MCT inhibitors on cell invasion capacity. Cells were treated with the 
respective IC50/2 (CHC) and IC50 (Quercetin/Lonidamine) values, for 24 hours, in matrigel invasion 
chambers. Pictures represent MDA-MB-468 cell invasion at 24 hours (scale bar 100µm and 2000 µm).  
110x110mm (300 x 300 DPI)  
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Supplemental Figure 1. Effect of CHC inhibitor on glycolitic metabolism. 
Extracellular amounts of consumed glucose (A) and lactate produced (B) in the 
different human breast cancer cell lines. Cell lines were incubated with respective 
IC50/2 for CHC, during 24 hours, and glucose and lactate were quantified along time (4, 
8, 12 and 24 hours). Values are expressed as mean ± SEM. p<0.05; *Control (DMSO) 
vs CHC.  
Supplemental Figure 2. Effect of MCT inhibitors on cell migration. Cell migration 
was evaluated by the wound-healing assay in treated cells during 24 hours with the 
IC50/2 for CHC and the IC50 for Quercetin and Lonidamine. Pictures represent MDA-
MB-468, MCF-7/AZ and SkBr3 cell migration captured at 0, 12 and 24 hours (scale bar 
100µm). 
Supplemental Figure 3. Effect of MCT inhibitors on cell invasion capacity. Cells 
were treated with the respective IC50/2 (CHC) and IC50 (Quercetin/Lonidamine) values, 
for 24 hours, in matrigel invasion chambers. Pictures represent MDA-MB-468 cell 
invasion at 24 hours (scale bar 100µm and 2000 µm). 
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